Cost-effectiveness of Ribociclib in HER2- negative breast cancer: A synthesis of current evidence

BACKGROUND: The main aim of this study was to investigate the cost-effectiveness of Ribociclib in the treatment of patients with breast cancer by assessing the published evidence. METHOD: A systematic review of the published literature was conducted to identify the economic evaluations/cost-effectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Alotaibi, Wedad H., Alhamdan, Majd M., Balkhi, Bander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508637/
https://www.ncbi.nlm.nih.gov/pubmed/36164576
http://dx.doi.org/10.1016/j.jsps.2022.06.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508637/
https://www.ncbi.nlm.nih.gov/pubmed/36164576
http://dx.doi.org/10.1016/j.jsps.2022.06.002

Ejemplares similares